| Recruiting | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | 2023-10-02 |
| Completed | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Ca Adenocarcinoma of the Prostate | Phase 3 | 2018-10-18 |
| Completed | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Metastatic Prostate Cancer | Phase 2 | 2013-09-01 |
| Terminated | Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Prostate Cancer | — | 2012-10-01 |
| Completed | Sipuleucel-T Manufacturing Demonstration Study Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate | Phase 2 | 2012-06-01 |
| Terminated | Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Castration-Resistant Prostate Cancer | — | 2012-01-01 |
| Terminated | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Prostate Cancer | Phase 2 | 2011-12-01 |
| Completed | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prost Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | 2011-12-01 |
| Completed | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma | Phase 2 | 2011-09-01 |
| Terminated | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Urothelial Carcinoma | Phase 2 | 2011-06-01 |
| Completed | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer Advanced Prostate Cancer, Prostatic Neoplasms | — | 2011-01-27 |
| Completed | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer Prostate Cancer | Phase 2 | 2009-10-01 |
| Completed | Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors Solid Tumors | Phase 1 | 2009-03-01 |
| Completed | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen Prostate Cancer | Phase 2 | 2008-10-01 |
| Completed | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer Prostate Cancer | Phase 2 | 2008-07-01 |
| Completed | Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) Metastatic Androgen Independent Prostate Cancer | Phase 2 | 2004-04-01 |
| Completed | Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing H Prostate Cancer | Phase 3 | 2003-07-01 |
| Completed | PROvenge Treatment and Early Cancer Treatment Prostate Cancer | Phase 3 | 2001-10-01 |
| Completed | Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Hormone-Refractory Prostate Cancer | Phase 3 | 2000-05-01 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Prostate Cancer | Phase 3 | 1999-11-01 |